Can We Treat Mood Disorders With Pharmacological Therapeutics?

| February 1, 2019

article image
Clinical treatments for neurological and mood disorders like anxiety disorder (SAD) and major depressive disorder (MDD) have failed to show consistent efficacy in treating patients. VistaGen Therapeutics is aiming to correct that. VistaGen’s compound AV-101, an NMDA receptor antagonist, is currently in clinical trials for MDD and suicidal ideation, with clinical studies for neuropathic pain and Parkinson's disease levodopa-induced dyskinesia (PDLID) on the horizon. Additionally, VistaGen’s PH94B molecule is being prepared for a Phase 3 clinical program for SAD as a first-in-class nasal spray.

Spotlight

AMCo (Formerly Amdipharm Mercury Ltd)

AMCo is a rapidly-growing international pharmaceutical company. We supply niche medicines that make a real difference to the patients, doctors, hospitals and healthcare authorities we serve in over 100 countries worldwide.

OTHER ARTICLES

3 Big Pharma Stocks Plunging the Most During the Coronavirus Stock Market Crash: Are They Buys?

Article | March 26, 2020

Big pharma stocks have been clobbered during the coronavirus-caused stock market crash. You can count the number of drugmakers with market caps of $25 billion or more whose shares haven't dropped by double-digit percentages on one hand -- and have several fingers left over. Three big pharma stocks have plunged the most: AbbVie (NYSE:ABBV), Bristol Myers Squibb (NYSE:BMY), and Pfizer (NYSE:PFE). But are these stocks smart picks to buy right now?

Read More
PHARMACY MARKET

A pharma outsourcing mission

Article | March 26, 2020

In a way, getting through the initial stages of a complex pharmaceutical project that is being outsourced to a contract development and manufacturing organization is like getting a rocket off the ground. Many drug developers express frustration with the time it often takes during the initial stages of working with a CDMO — from the time they first reach out to a CDMO for help until they receive a proposal. Some have described it as months of silence from when they send a request for proposal (RFP) until they have a proposal in hand. The initial stages of a relationship between drug sponsor and CDMO often do not get the attention it deserves, and valuable time is lost, delaying projects and delaying delivery of therapeutics to patients. The quick scheduling of the ACT meeting with the right attendees can deliver immediate answers to key questions needed by the drug sponsor for effective planning and can help propel projects to a successful launch.

Read More

Pfizer Won’t Win the Coronavirus Pharma War

Article | March 26, 2020

Shares of Pfizer jumped more than 6% on Wednesday, after the company announced a plan to test some of its antiviral products as a potential treatment for the coronavirus from China. More than 35 million shares traded on the news — about 48% more than normal — as investors looked for any positive news from the pharma community after the recent selloff. So, does this mean that Pfizer stock is turning the corner?

Read More

Merck’s Patient-Centric Clinical Trial Recruiting

Article | March 26, 2020

Everyone in pharma knows that product success depends on the results of clinical trials — but we don’t usually hear from the people who are involved in running them. Recently, four Clinical Research Managers (CRM) from Merck (known as MSD outside the United States and Canada) discussed how Merck is overcoming the barriers to clinical trial recruitment by adopting a patient-centric process — a model that affects their trials top to bottom, from design through implementation. Each of the panel members manages clinical trials, serving as the main point of interaction with the Clinical Research Associates (CRAs) on research requirements, goals, and resources, including recruiting and retention.

Read More

Spotlight

AMCo (Formerly Amdipharm Mercury Ltd)

AMCo is a rapidly-growing international pharmaceutical company. We supply niche medicines that make a real difference to the patients, doctors, hospitals and healthcare authorities we serve in over 100 countries worldwide.

Events